相关实验视频

Updated: Aug 1, 2026

The Influence of Liver Resection on Intrahepatic Tumor Growth

The Influence of Liver Resection on Intrahepatic Tumor Growth

Published on: April 9, 2016

采用免疫疗法降低肝细胞癌的术后复发率:一项随机试验

T Takayama¹, T Sekine, M Makuuchi

¹Department of Surgery, National Cancer Centre Research Institute, University of Tokyo, Japan. takayamat-2su@h.u-tokyo.ac.jp

Lancet (London, England)

|October 7, 2000

概括

在一项随机试验中,术后采用免疫疗法显著降低了肝细胞癌 (HCC) 复发率. 这种治疗改善了无复发的生存率,为接受HCC手术的患者提供了一个有前途的策略.

科学领域:

肝胆道手术是肝胆道的手术.
免疫治疗是一种免疫疗法.
在瘤学瘤学.

背景情况:

手术后肝细胞癌 (HCC) 复发是一个重大的临床挑战.
收养免疫疗法已经证明对HCC的活性.

研究的目的:

评估术后采用免疫疗法在降低HCC复发率方面的疗效.

主要方法:

一项随机试验,涉及150名接受治愈性HCC切除的患者.
患者接受了采用免疫疗法或没有辅助治疗.
免疫疗法包括在6个月内输注激活的自身淋巴细胞.

主要成果:

与对照组相比,采用免疫疗法减少了18%的复发.
在免疫疗法组中观察到,第一次复发的时间显著更长,并且在免疫疗法组中改善了无复发生存率.
疾病特异性存活率也显著改善,整体存活率没有差异.

结论:

采用免疫疗法是一种安全且可行的HCC辅助治疗方法.
它有效降低了复发率,并提高了手术切除后的无复发结果.

更多相关视频

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.